By Davit Kirakosyan
Citi downgraded Mirati Therapeutics (NASDAQ:MRTX) to Neutral from Buy and lowered its price target to $53.00 from $121.00. Shares plunged more than 52% in the last 3 days after the company’s lung cancer therapy (adagrasib) data disappointed investors.
Baird downgraded Salesforce Inc (NYSE:CRM) to Neutral from Outperform and lowered its price target to $150.00 from $200.00 given the tough macro environment, seat-based software pressure, and the recent executive departures.
JPMorgan downgraded Sinclair Broadcast Group Inc (NASDAQ:SBGI) to Underweight from Neutral and cut its price target to $16.00 from $25.00. Shares closed more than 3% lower today.
BTIG downgraded Unity Software Inc (NYSE:U) to Neutral from Buy.
Want to get this news first? Upgrade to InvestingPro for real-time market coverage.
Is CRM truely undervalued?
With CRM making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed CRM alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? CRM wasn't at the top of the list.
Unlock ProPicks AI